Eli Lilly (LLY) on Friday announced plans to invest more than $3.5B to build a new manufacturing facility in Lehigh Valley, Pennsylvania, to develop its next-generation weight-loss medicines, including its “triple G” agonist retatrutide.
The manufacturing facility will focus on producing the company’s next-generation weight-loss therapies, including retatrutide, the Indiana-based drugmaker said, adding that it is the fourth U.S. production site it has announced since February 2025.
Eli Lilly (LLY) plans to begin its construction work this year, generating 2,000 construction jobs. The injectable medicine and device site is expected to launch in 2031, creating 850 high-value jobs in the area.
The pharma giant has already posted Phase 3 data showing that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, can generate up to 24% of weight loss.
